Results 121 to 130 of about 80,018 (239)

Epidemiology and Genetics of Rheumatic Diseases Suggest a Constant Rate of DNA Damage as Underlying Cause

Immunology, Volume 177, Issue 4, Page 736-748, April 2026.
A constant rate of DNA damage that is not perfectly repaired will cause a constant rate of DNA mutations. The chance of mutation will increase if DNA is prone to damage, such as occurs in somatic hypermutation (SHM) hotspots and GC‐rich DNA. Thus, if one mutation‐prone DNA site drives disease, the age of onset of disease and degree of penetrance should
Piet C. de Groen
wiley   +1 more source

Elephantiasis nostras verrucosa: an atypical presentation following intrapelvic lymphoma [PDF]

, 2019
Elephantiasis nostras verrucosa is a progressively debilitating and disfiguring disease commonly presenting with verrucous, cobblestone-like papules, nodules, or plaques with nonpitting edema in the lower extremities.
Dahle, Sara E, Hadian, Yasmin, Isseroff, R Rivkah, Link, Daniel   +3 more
core  

Anti‐CD146 Autoantibodies: The First Biologic Markers Associated With Occupational Exposure in Systemic Sclerosis

ACR Open Rheumatology, Volume 8, Issue 3, March 2026.
Objective Systemic sclerosis (SSc) is a severe autoimmune disease, with occupational exposure being a significant risk factor. Because CD146 was recently identified as a driver of fibrosis in SSc through regulation of the Wnt/reactive oxygen species interplay, we hypothesized that it is a major autoimmune target in this disease. Methods We developed an
Julien Bermudez, Xavier Heim, Elise Kaspi, Charlotte Reytier, Abdelouahab Beziane, Robin Arcani, Audrey Benyamine, Brigitte Granel, Antoine Villa, Marcel Blot‐Chabaud, Erwan Dumontet, Christophe Paris, Alain Lescoat, Valérie Lecureur, Nathalie Bardin   +14 more
wiley   +1 more source

Distinct by Design: Unraveling the Unique Clinical and Transcriptomic Identity of Juvenile Scleromyositis Overlap Compared to Juvenile Systemic Sclerosis and Juvenile Dermatomyositis: Implications for Care and Pathogenesis

ACR Open Rheumatology, Volume 8, Issue 3, March 2026.
Objective To characterize clinical and transcriptomic differences in juvenile scleromyositis overlap (jOverlap) compared to juvenile systemic sclerosis (jSSc) and juvenile dermatomyositis (JDM), focusing on autoantibody profiles, organ involvement, treatment, and peripheral blood gene expression.
Amanda D. Robinson, Clare E. Pain, Gabrielle A. Morgan, Anwesha Sanyal, Srilakshmi Chaparala, Lauren M. Pachman, Kathryn S. Torok   +6 more
wiley   +1 more source

Author Correction: Fibroblast A20 governs fibrosis susceptibility and its repression by DREAM promotes fibrosis in multiple organs

Nature Communications, 2023
Wenxia Wang, Swarna Bale, Jun Wei, Bharath Yalavarthi, Dibyendu Bhattacharyya, Jing Jing Yan, Hiam Abdala-Valencia, Dan Xu, Hanshi Sun, Roberta G. Marangoni, Erica Herzog, Sergejs Berdnikovs, Stephen D. Miller, Amr H. Sawalha, Pei-Suen Tsou, Kentaro Awaji, Takashi Yamashita, Shinichi Sato, Yoshihide Asano, Chinnaswamy Tiruppathi, Anjana Yeldandi, Bettina C. Schock, Swati Bhattacharyya, John Varga   +23 more
doaj   +1 more source

Scleroderma [PDF]

Ear, Nose & Throat Journal, 2011
Michele P, Morrison, Paul M, Weinberger, Gregory N, Postma   +2 more
openaire   +2 more sources

Performance of Circulating Inflammatory Biomarkers and Krebs von den Lungen 6 for Predicting Progressive Pulmonary Fibrosis in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease

ACR Open Rheumatology, Volume 8, Issue 3, March 2026.
Objective To assess the predictive performance of inflammatory biomarkers, including C‐reactive protein (CRP) and Krebs von den Lungen 6 (KL‐6), for the development of progressive pulmonary fibrosis (PPF) in patients with systemic sclerosis (SSc)–associated interstitial lung disease (ILD).
Keina Yomono, Suiyuan Huang, Dinesh Khanna, Masataka Kuwana   +3 more
wiley   +1 more source

Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease

Arthritis &Rheumatology, Volume 78, Issue 3, Page 566-581, March 2026.
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman, Voon Ong, Christopher P. Denton   +2 more
wiley   +1 more source

Association of Abatacept With Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis–Associated Interstitial Lung Disease: An Emulated Target Trial

Arthritis &Rheumatology, Volume 78, Issue 3, Page 592-602, March 2026.
Objective The optimal treatment strategy for rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) remains uncertain, and direct comparative data between biologics are limited. This study aimed to evaluate the effectiveness and safety of abatacept compared with rituximab in patients with RA‐ILD.
Po‐Cheng Shih, Shiow‐Ing Wang, James Cheng Chung Wei   +2 more
wiley   +1 more source

The Potential Role of Butyrate in the Pathogenesis and Treatment of Autoimmune Rheumatic Diseases

Biomedicines
The gut microbiota is a complex ecosystem of microorganisms residing in the human gastrointestinal tract, playing a crucial role in various biological processes and overall health maintenance.
Carmela Coccia, Francesco Bonomi, Anna Lo Cricchio, Edda Russo, Silvia Peretti, Giulia Bandini, Gemma Lepri, Francesca Bartoli, Alberto Moggi-Pignone, Serena Guiducci, Francesco Del Galdo, Daniel E. Furst, Marco Matucci Cerinic, Silvia Bellando-Randone   +13 more
doaj   +1 more source